Real-World Study Finds ERLEADA Cuts Death Risk in Advanced Prostate Cancer
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) reported new real-world evidence showing that patients with metastatic castration-sensitive prostate cancer who began treatment with ERLEADA without chemotherapy experienced a sharply …
Real-World Study Finds ERLEADA Cuts Death Risk in Advanced Prostate Cancer Read More